Every GLP-1 Medication Ever Approved: Complete List
A comprehensive catalog of every GLP-1 receptor agonist approved by the FDA, plus key investigational drugs in the pipeline.
The GLP-1 receptor agonist class has grown from a single twice-daily injection in 2005 to a diverse family of medications targeting weight loss, diabetes, cardiovascular protection, and beyond. This reference lists every approved drug plus the most promising pipeline candidates.
FDA-Approved GLP-1 Receptor Agonists
Complete Approved Drug List
| Generic | Brand(s) | Approved | Type | Frequency |
|---|---|---|---|---|
| Exenatide | Byetta | 2005 | GLP-1 | Twice daily |
| Liraglutide | Victoza, Saxenda | 2010, 2014 | GLP-1 | Daily |
| Exenatide ER | Bydureon | 2012 | GLP-1 | Weekly |
| Albiglutide | Tanzeum | 2014 | GLP-1 | Weekly (discontinued) |
| Dulaglutide | Trulicity | 2014 | GLP-1 | Weekly |
| Lixisenatide | Adlyxin | 2016 | GLP-1 | Daily |
| Semaglutide | Ozempic, Wegovy, Rybelsus | 2017-2021 | GLP-1 | Weekly/Daily oral |
| Tirzepatide | Mounjaro, Zepbound | 2022-2023 | GIP/GLP-1 | Weekly |
Key Pipeline Drugs (Investigational)
| Drug | Company | Mechanism | Phase | Key Data |
|---|---|---|---|---|
| Retatrutide | Eli Lilly | GLP-1/GIP/Glucagon | Phase 3 | 24.2% weight loss |
| Orforglipron | Eli Lilly | Oral GLP-1 | Phase 3 | ~15% weight loss |
| Survodutide | Boehringer | GLP-1/Glucagon | Phase 3 | ~19% weight loss |
| Amycretin | Novo Nordisk | Amylin/GLP-1 | Phase 2 | ~13% at 12 weeks |
| Pemvidutide | Altimmune | GLP-1/Glucagon | Phase 2 | ~16% weight loss |
Weight Loss Efficacy Comparison
Across clinical trials, the progression is clear: each generation of GLP-1-based therapy delivers substantially more weight loss. First-generation GLP-1s (liraglutide/Saxenda) averaged ~8% body weight loss. Second-generation (semaglutide/Wegovy) jumped to 15-17%. Dual agonists (tirzepatide/Zepbound) reached 20-22.5%. And triple agonists (retatrutide) have shown 24%+ with weight curves still declining at study end.
Accessing GLP-1 Medications Through Trimi
Trimi offers all three current generations: compounded semaglutide ($99/mo), tirzepatide ($125/mo), and retatrutide. Our physicians help match each patient with the optimal medication based on their goals, medical history, and budget.
Find Your Optimal GLP-1
From first-generation to cutting-edge triple agonists. Trimi has them all.
View TreatmentsMedical Disclaimer
This reference is for educational purposes. Pipeline drugs are investigational and not FDA-approved. Clinical trial results cited are from published studies. Always consult your healthcare provider for treatment decisions.
More on GLP-1 reference
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).